Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof

A method for the treatment of respiratory diseases and allergic diseases of the airways comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I)

• wherein
• A denotes a bond or is selected from the group consisting of O, —CH2—, —CH2CH2—, —CH2CH2CH2—, —CH2—O—, —CH2—NRA1— and —NRA1—,
• wherein
• RA1 denotes hydrogen or C1-6-alkyl,
• B denotes
• —CH2— or —CH2CH2—, or
• provided that A is not O or —NRA1, B denotes a bond
• D, E denote independently from each other a bond or —CH2—,
• F denotes optionally substituted aryl,
• or optionally substituted heteroaryl,
• G denotes a group of formula (g.1), (g.2) or (g.3)
• wherein
• R1 is selected from the group consisting of
• hydrogen, C1-6alkyl, optionally substituted piperidinyl-CO—,
• optionally substituted piperazinyl-CO—, R1.1—SO2—, R1.2—C2-4-alkyl-NH—CO—, H3C—NH—CO—, R1.2.4—O—CO—CH2—NH—CO—, R1.2—C2-4-alkyl-N(C1-4-alkyl)-CO—, H3C—N(C1-4-alkyl)-CO—, R1.2.4—O—CO—CH2—N(C1-4-alkyl)-CO—, R1.3—C1-6-alkyl-, R1.4—C2-6-alkyl-, optionally substituted phenyl-CH2—, C1-6-alkyl-O—CO—, R1.4.3—O—CO—CH2—, HO—CO—CH2— and HOSO2—CH2—,
• R1.5—C1-6-alkyl-CO— and R1.6—C(NH)—,
• wherein
• R1.1 is selected from the group consisting of C1-4-alkyl-,
• H2NC(NH)NH—C1-6-alkyl-, R1.2.1R1.2.2N—C1-4-alkyl-,
• R1.2.1R1.2.2R1.2.3N+—C1-4-alkyl, HOCO—C1-4-alkyl- and
• C1-3-alkyl-OCO—C1-4-alkyl-,
• R1.2 is selected from the group consisting of hydrogen, H2NC(NH)NH—, R1.2.1R1.2.2N—, R1.2.1R1.2.2R1.2.3N+—, R1.2.3—HN—C(NR1.2.3)—NH—, R1.2.4—O—CO—,
• R1.2.5—O—CO—NH— and HO—CO—, HOSO2—,
• wherein
• R1.2.1 denotes hydrogen or C1-6-alkyl,
• R1.2.2 denotes hydrogen or C1-6-alkyl,
• or
• R1.2.1 and R1.2.2 together form a 4- to 7-membered heterocyclic ring containing one N-atom,
• R1.2.3 denotes hydrogen or C1-6-alkyl,
• R1.2.4 denotes hydrogen or C1-6-alkyl,
• R1.2.5 denotes hydrogen or C1-6-alkyl,
• R1.3 is selected from the group consisting of hydrogen, C1-6-alkyl, C1-6-alkyl-O—, optionally substituted phenyl, R1.3.1R1.3.2N—, R1.2.1R1.2.2R1.2.3N+—,
• R1.2.3—HN—C(NR1.2.3)—NH—, H2NC(NH)NH—, R1.2.4—O—CO—, HO—CO— and HOSO2—,
• wherein
• R1.3.1 denotes hydrogen or C1-6-alkyl,
• R1.3.2 denotes hydrogen or C1-6-alkyl,
• or
• R1.3.1 and R1.3.2 together form a 4- to 7-membered heterocyclic ring containing one N-atom,
• R1.4 is selected from the group consisting of hydrogen, R1.4.1R1.4.2N—,
• R1.4.1R1.4.2R1.4.3N+—, H2N—C(NH)—NH—, R1.4.3—HN—C(NR1.4.4)—NH—, optionally substituted phenyl, R1.4.3—O—CO—, R1.4.4—O—CO—NH—, HO—CO— and HOSO2—,
• wherein
• R1.4.1 denotes hydrogen or C1-6-alkyl,
• R1.4.2 denotes hydrogen or C1-6-alkyl,
• R1.4.3 denotes hydrogen or C1-6-alkyl,
• R1.4.4 denotes hydrogen or C1-6-alkyl,
• R1.5 is selected from the group consisting of hydrogen, C1-6-alkyl-O—,
• R1.5.1R1.5.2N—, R1.5.2R1.5.3N+—, H2N—C(NH)—NH—, optionally substituted phenyl, R1.5.3—O—CO—, R1.5.4—O—CO—NH—, HO—CO— and HOSO2—,
• wherein
• R1.5.1 denotes hydrogen or C1-6-alkyl,
• R1.5.2 denotes hydrogen or C1-6-alkyl,
• R1.5.3 denotes hydrogen or C1-6-alkyl,
• R1.5.4 denotes hydrogen or C1-6-alkyl,
• R1.6 denotes R1.6.1R1.6.2N—,
• wherein
• R1.6.1 denotes hydrogen or C1-6-alkyl;
• R1.6.2 denotes hydrogen or C1-6-alkyl;
• R1b is selected from the group consisting of C11-4-alkyl,
• R1.4—C2-6-alkyl-, optionally substituted phenyl-CH2—, R1.4.3—O—CO—CH2— and HO—CO—CH2—
• R1s denotes C1-6-alkyl,
• X− denotes any anion forming a pharmaceutically acceptable salt,
• L denotes a bridging group —CO—NH—C2-6-alkyl-NH—CO—, —COC1-6-alkyl-CO—, —C2-6-alkyl-,
• forming a compound of formula (IC),
• whereby the molecular entities of formula (IC) connected by L may be identical or different
• R5 denotes Cl or Br,
• or a pharmacologically acceptable acid addition salt thereof.